D. Boral Capital Has Lowered Expectations for Quince Therapeutics (NASDAQ:QNCX) Stock Price

Quince Therapeutics (NASDAQ:QNCX) had its price target lowered by equities researchers at D. Boral Capital from $12.00 to $4.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. D. Boral Capital’s target price suggests a potential upside of 185.71% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Oppenheimer began coverage on shares of Quince Therapeutics in a report on Monday. They issued an “outperform” rating and a $10.00 price target for the company. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Quince Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $1.40 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The company has a 50 day moving average price of $1.49 and a 200-day moving average price of $1.44. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45. The firm has a market cap of $61.60 million, a price-to-earnings ratio of -1.13 and a beta of 0.71.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million during the quarter. Equities research analysts forecast that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Quince Therapeutics

A number of hedge funds have recently modified their holdings of the business. Anfield Capital Management LLC purchased a new stake in Quince Therapeutics during the 4th quarter valued at about $50,000. Virtu Financial LLC purchased a new position in Quince Therapeutics in the 4th quarter worth approximately $55,000. Two Sigma Investments LP acquired a new position in shares of Quince Therapeutics during the 4th quarter worth approximately $57,000. Northern Trust Corp grew its position in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares in the last quarter. Finally, Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter valued at approximately $170,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.